ArticleCureus2025
Comparative Analysis of Oncotype DX Recurrence Scores in Screen‑Detected Versus Symptomatic Early‑Stage Breast Cancer: The COSSEB Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancers detected through population-based screening mammography (screen-detected breast cancers, SDBCs) typically differ from cancers first identified after symptom onset (symptomatic breast cancers, SBCs) in stage and biology. We investigated whether these clinical differences extend to genomic risk as measured by the 21-gene Oncotype DX Recurrence score (ODX-RS), which guides adjuvant treatment in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, and examined whether presentation mode influenced adjuvant treatment recommendations.
methodsWe performed a retrospective analysis of 200 women aged ≥50 years who underwent surgery for ER-positive, HER2-negative early breast cancer between 2017 and 2025. The cohort comprised 100 SDBCs and 100 age-matched SBCs, all of whom had low-burden axillary disease and successful ODX-RS testing. Clinicopathologic features, ODX-RS categories (≤25 vs ≥26), and adjuvant treatment recommendations were compared between groups using counts/percentages (or differences for continuous variables) with two-tailed P values; adjusted associations, where applicable, are reported as odds ratios (ORs) with 95% confidence intervals.
resultsSDBCs were smaller (median 24 mm vs 28 mm; median difference -4 mm (95% CI -7 to -0.5); P=0.05) and more frequently treated with breast-conserving surgery (77% vs 61%; P=0.01). Low HER2 expression (immunohistochemistry 1+) was more common in SDBCs (54% vs 38%; P=0.014). An ODX-RS ≥26 occurred slightly more often in SBCs than SDBCs (21% vs 17%; P=0.47), and subgroup analyses by tumor size and grade showed largely similar score distributions between groups. Adjuvant chemotherapy was recommended for 23% of SBCs and 19% of SDBC cases (P=0.49); endocrine therapy was advised for most patients in both cohorts.
conclusionsScreen-detected and symptomatic ER-positive/HER2-negative early breast cancers exhibited broadly comparable ODX-RS distributions. Mode of presentation alone should therefore not dictate adjuvant chemotherapy decisions; multigene testing and standard clinicopathologic factors remain essential for individualized treatment planning. Larger, prospective studies are warranted to validate and extend these observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.